Trade Windtree Therapeutics, Inc. - WINT CFD

Trading Conditions

• Spread: 0.2470
• Long position overnight feeLong position overnight feeMargin. Your investmentUS$1,000.00Overnight feeCharges from full value of position-0.026179 %(-US$1.05)Trade size with leverage ~ US$5,000.00Short position overnight fee ~ US$4,000.00Go to platform: -0.026179%
• Short position overnight feeShort position overnight feeMargin. Your investmentUS$1,000.00Overnight feeCharges from full value of position0.003957 %(US$0.16)Trade size with leverage ~ US$5,000.00Short position overnight fee ~ US$4,000.00Go to platform: 0.003957%
• Overnight fee time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 0.01
• Margin: 20
• Stock exchange: United States of America
• Commission on trade: 0%

• Margin. Your investment: US$1,000.00
• Overnight feeCharges from full value of position: -0.026179 %
  (-US$1.05)

• Margin. Your investment: US$1,000.00
• Overnight feeCharges from full value of position: 0.003957 %
  (US$0.16)

Key Stats

• Prev. Close: 5.0365
• Open: 5.0565
• 1-Year Change: 175.6%
• Day's Range: 5.0565 - 5.3465

Windtree Therapeutics Inc. Company profile

About Windtree Therapeutics Inc

Windtree Therapeutics, Inc. is a clinical-stage biopharmaceutical and medical device company. The Company’s development programs are primarily focused on the treatment of acute cardiovascular and acute pulmonary diseases. The Company’s cardiovascular programs includes Istaroxime (Early Cardiogenic Shock), Istaroxime (acute heart failure), Rostafuroxin and Oral SERCA2a Activators. Its Pulmonary Programs include Lyophilized KL4 Surfactant and AEROSURF (aerosolized KL4 surfactant based on Aerosol Delivery System technology). The Company’s subsidiaries Discovery Laboratories, Inc., CVie Investments Limited and CVie Therapeutics Limited.

Financial summary

BRIEF: For the nine months ended 30 September 2021, Windtree Therapeutics Inc revenues was not reported. Net loss increased from $25.1M to $54.6M. Higher net loss reflects Research and development - Balancing val increase of 8% to $11.1M (expense), Stock-based Compensation in R and D increase of 39% to $2.3M (expense), Stock-based Compensation in SGA increase of 21% to $3.4M (expense).

Equity composition

Common Stock $.015 Par, 04/11, 50M auth., 13,822,000 issd., less 21,000 shs. in Treas. @ $3.1M. Insiders own 1.88%. *NOTE: 12/97 Name changed from Ansan Pharmaceuticals; FY'00 Qs are restated. *2/05, PO 5.06M shares @ $5.75 by SG Cowen & Co., LLC. 12/10, 1-for-15 reverse split. 01/06, 1-for-14 reverse stock split